Neonatal Immunity to<i>Bordetella pertussis</i>Infection and Current Prevention Strategies

Correia, Carolina Argondizo; Rodrigues, Ana Kelly S.; Brito, Cyro Alves de

doi:10.1155/2019/7134168

Cited by 23 publications

(14 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a bias toward Th2 differentiation in neonates [ 58 , 84 ]. This may reflect high expression of IL-4 and the Th2 transcription factor, GATA3 and hypomethylation of the Th2 locus, which includes il4 , il13 and il5 genes [ 85 , 86 , 87 ].…”

Section: Natural and Vaccine-induced Immunity-correlates Of Protecmentioning

confidence: 99%

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Chasaide

Mills

2020

Vaccines

View full text Add to dashboard Cite

Immunization with current acellular pertussis (aP) vaccines protects against severe pertussis, but immunity wanes rapidly after vaccination and these vaccines do not prevent nasal colonization with Bordetella pertussis. Studies in mouse and baboon models have demonstrated that Th1 and Th17 responses are integral to protective immunity induced by previous infection with B. pertussis and immunization with whole cell pertussis (wP) vaccines. Mucosal Th17 cells, IL-17 and secretory IgA (sIgA) are particularly important in generating sustained sterilizing immunity in the nasal cavity. Current aP vaccines induce potent IgG and Th2-skewed T cell responses but are less effective at generating Th1 and Th17 responses and fail to prime respiratory tissue-resident memory T (TRM) cells, that maintain long-term immunity at mucosal sites. In contrast, a live attenuated pertussis vaccine, pertussis outer membrane vesicle (OMV) vaccines or aP vaccines formulated with novel adjuvants do induce cellular immune responses in the respiratory tract, especially when delivered by the intranasal route. An increased understanding of the mechanisms of sustained protective immunity, especially the role of respiratory TRM cells, will facilitate the development of next generation pertussis vaccines that not only protect against pertussis disease, but prevent nasal colonization and transmission of B. pertussis.

show abstract

Section: Natural and Vaccine-induced Immunity-correlates Of Protecmentioning

confidence: 99%

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Chasaide

Mills

2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…Bordetella pertussis is a Gram-negative coccobacillus that causes whooping cough and persistent cough, especially in neonates, school-aged children and adolescents [71,72].…”

Section: Pertussis Vaccinationmentioning

confidence: 99%

Vaccination against Paediatric Respiratory Pathogens

et al. 2019

View full text Add to dashboard Cite

Acute respiratory infections (ARIs) are extremely common in children, especially those under 5 years old. They can lead to complications, super-infection, respiratory failure, and even compromised respiratory function in adulthood. For some of the responsible pathogens, vaccines are available. This review reports current issues about vaccines against the main respiratory pathogens to highlight the available strategies to reduce the burden of paediatric respiratory disease. The optimal use of influenza, pneumococcal, pertussis and measles vaccines is required in order to reduce ARI burden. Vaccination coverage rates must be improved to achieve the full benefits of these vaccines. Recently, advances in the knowledge of respiratory syncytial virus structural biology and immunology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines even against this harmful pathogen.

show abstract

“…Recovery (convalescence) from the disease is a gradual process, with the episodes of coughing subsiding over the course of months. Pertussis tends to be more severe in infants and young children compared with older children, adolescents and adults, owing to a qualitative difference in the immune system because of a lag in thymic maturation; even in adults, immunity is not permanent as evidenced by the reemergence of disease after prior infection or previous vaccination [ 1 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Acellular Pertussis Vaccine Components: Today and Tomorrow

Dewan

Linz

DeRocco³

et al. 2020

Vaccines

View full text Add to dashboard Cite

Pertussis is a highly communicable acute respiratory infection caused by Bordetella pertussis. Immunity is not lifelong after natural infection or vaccination. Pertussis outbreaks occur cyclically worldwide and effective vaccination strategies are needed to control disease. Whole-cell pertussis (wP) vaccines became available in the 1940s but have been replaced in many countries with acellular pertussis (aP) vaccines. This review summarizes disease epidemiology before and after the introduction of wP and aP vaccines, discusses the rationale and clinical implications for antigen inclusion in aP vaccines, and provides an overview of novel vaccine strategies aimed at better combating pertussis in the future.

show abstract

Neonatal Immunity toBordetella pertussisInfection and Current Prevention Strategies

Cited by 23 publications

References 96 publications

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract

Vaccination against Paediatric Respiratory Pathogens

Acellular Pertussis Vaccine Components: Today and Tomorrow

Contact Info

Product

Resources

About